AnaptysBio (ANAB) to Release Quarterly Earnings on Thursday

AnaptysBio (NASDAQ:ANAB) will likely be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.89 per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

AnaptysBio Stock Up 2.1%

Shares of ANAB stock opened at $54.83 on Thursday. The company has a market cap of $1.52 billion, a P/E ratio of -19.44 and a beta of 0.35. The business has a 50 day moving average of $48.42 and a two-hundred day moving average of $36.27. AnaptysBio has a 52 week low of $13.99 and a 52 week high of $57.65.

AnaptysBio announced that its Board of Directors has initiated a stock repurchase program on Friday, November 21st that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wells Fargo & Company increased their target price on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Barclays upped their price target on shares of AnaptysBio from $55.00 to $78.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. UBS Group started coverage on shares of AnaptysBio in a research report on Wednesday, January 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Stifel Nicolaus reduced their target price on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Finally, Wedbush restated an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a research note on Monday, November 24th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus target price of $66.89.

Insider Activity at AnaptysBio

In other news, CEO Daniel Faga sold 15,309 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $43.26, for a total value of $662,267.34. Following the sale, the chief executive officer owned 458,139 shares of the company’s stock, valued at approximately $19,819,093.14. The trade was a 3.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric J. Loumeau sold 12,500 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $44.86, for a total value of $560,750.00. Following the transaction, the insider directly owned 9,088 shares of the company’s stock, valued at $407,687.68. This represents a 57.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 156,280 shares of company stock valued at $7,254,939. Insiders own 33.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently made changes to their positions in ANAB. Los Angeles Capital Management LLC raised its holdings in shares of AnaptysBio by 1.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock worth $732,000 after purchasing an additional 225 shares in the last quarter. Larson Financial Group LLC grew its position in AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares during the last quarter. Susquehanna Portfolio Strategies LLC increased its holdings in shares of AnaptysBio by 1.4% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock valued at $1,743,000 after buying an additional 500 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares in the last quarter. Finally, Orion Porfolio Solutions LLC lifted its position in shares of AnaptysBio by 7.0% during the 4th quarter. Orion Porfolio Solutions LLC now owns 14,697 shares of the biotechnology company’s stock valued at $713,000 after acquiring an additional 958 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.